Enhancing the response to avian influenza in the US and globally
- PMID: 40625789
- PMCID: PMC12230410
- DOI: 10.1016/j.lana.2025.101100
Enhancing the response to avian influenza in the US and globally
Abstract
The recent emergence of highly pathogenic H5N1 avian influenza virus infections in dairy cows and humans in the U.S. has raised alarms regarding the potential for a pandemic. Over 995 dairy cow herds and at least 70 humans have been affected, including cases of severe disease and the first reported H5N1-related death in the U.S. Sporadic human infections with no known contact with infected animals highlight the possibility of viral adaptation for efficient human-to-human transmission. Concurrently, the virus continues to circulate in wild birds, backyard flocks, and hunted migratory species, further amplifying the risk to humans and domestic animals. This article provides an overview of the current outbreak status, emphasizes the importance of robust surveillance systems to detect emerging strains with pandemic potential, and highlights risks to the U.S. dairy and poultry industries. Recommendations for risk mitigation include enhanced biosecurity measures, improved surveillance, decentralized testing, and targeted public health messaging. The Global Virus Network calls for urgent, proactive measures to prevent widespread outbreaks, leveraging lessons learned from prior pandemics. These measures include targeted vaccination, improved communication strategies to combat vaccine hesitancy, and the incorporation of social sciences to address barriers to public health interventions.
Keywords: Global health; H5N1; Surveillance.
© 2025 Published by Elsevier Ltd.
Conflict of interest statement
SV is employed by the University of South Florida, holds a research grant from the NIH, serves on scientific advisory boards for Moderna, Tevogen Bio, Porosome Theraputics, and Immugen BioPharma. MB is employed by Johns Hopkins, holds a Ehlers Danlos research grant, advises Persistence Bio and Alveo, and is co-founder of CureX Technology and Infectious Insight. The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which FK is listed as inventor. The Icahn School of Medicine at Mount Sinai has also filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list FK as co-inventor and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. FK is co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, Gritstone and Avimex. The FK laboratory is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics.
References
-
- Garg S., Reinhart K., Couture A., et al. Highly pathogenic avian influenza A(H5N1) virus infections in humans. N Engl J Med. 2025;392(9):843–854. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
